Evaluation of thyroid and parathyroid functions in children receiving long-term carbamazepine therapy


Caksen H., Dulger H., Cesur Y., Atas B., Tuncer O., Odabas D.

INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol.113, no.9, pp.1213-1217, 2003 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 113 Issue: 9
  • Publication Date: 2003
  • Doi Number: 10.1080/00207450390232300
  • Journal Name: INTERNATIONAL JOURNAL OF NEUROSCIENCE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1213-1217
  • Van Yüzüncü Yıl University Affiliated: No

Abstract

We studied serum calcium, phosphorus, alkaline phosphatase (ALP), thyroid hormones (total thyroxine [TT4], free thyroxine [FT4], thyroid-stimulating hormone [TSH]), parathyroid hormone (PH), and osteocalcine levels in children with epilepsy who had been receiving long-term carbamazepine (CBZ) therapy to determine whether there was any effect of CBZ therapy on these hormones. The study included 18 patients with epilepsy receiving CBZ and 16 healthy age-matched controls. The age ranged from 4-18 years (11.26 +/- 3.59 years) and 4.5-17 years (11.16 +/- 3.13 years) in the study and control group, respectively. The duration of CBZ use was between 10 months-5 years (3.12 +/- 1.09 years). When comparing the results we did not find any significant difference in serum calcium, phosphorus, ALP, osteocalcine and TSH and PH levels between the groups (p > .05). However, serum TT4 and FT4 levels were found to be significantly lower in the study group than those of control group (p < .05). However, we observed no clinical signs of hypothyroidism in all subjects. To these findings we suggest that serum thyroid hormone levels should be monitored in children receiving long-term CBZ therapy.